Anthem Biosciences IPO: Anthem Biosciences IPO has made headlines this week with blockbuster oversubscription across all investor categories. The biotech-based CRDMO firm witnessed huge investor enthusiasm, with the issue being subscribed 63.86 times, led by QIBs bidding 182.65 times. With the IPO allotment status expected today, investors are keen to know whether they’ve hit the jackpot and what listing day may bring.
In this article, we break down everything from the allotment process, grey market premium (GMP), investor participation, and listing expectations — offering key insights in a crisp and clear format for Indian retail and institutional investors.
Anthem Biosciences IPO Grey Market Buzz: GMP Climbs to ₹158
The grey market premium (GMP) for Anthem Biosciences IPO has surged steadily post-bidding:
| Date | GMP (₹) | Trend |
|---|---|---|
| 18 July | ₹158 | Up |
| 17 July | ₹157 | Up |
| 16 July | ₹157 | Up |
| 15 July | ₹117 | Up |
| 14 July | ₹100 | Up |
| 12 July | ₹93 | Down |
Estimated Listing Price: ₹570 (IPO price) + ₹158 (GMP) = ₹728 per share, reflecting a 27% premium.
The rising GMP indicates strong listing day gains are anticipated, assuming stable market conditions.
Anthem Biosciences IPO: Key Details at a Glance
Here’s a snapshot of important IPO figures you need to know:
| Particulars | Details |
|---|---|
| IPO Name | Anthem Biosciences Ltd |
| IPO Open Date | 14 July 2025 |
| IPO Close Date | 16 July 2025 |
| Price Band | ₹540 – ₹570 per share |
| Lot Size | 26 shares |
| Issue Size (at upper price) | ₹3,395 crore |
| Type of Issue | 100% Offer for Sale (OFS) |
| Anchor Investment Raised | ₹1,016.02 crore |
| IPO Registrar | Kfin Technologies |
| Proposed Listing Date | 21 July 2025 |
| Listing Exchanges | BSE & NSE |
| Allotment Date | 17 July 2025 |
| Demat Credit & Refunds | 18 July 2025 |
Subscription Breakdown: Record Demand from QIBs & NIIs
The IPO drew robust demand from all categories. The Qualified Institutional Buyers (QIBs) dominated the charts, followed by Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs):
| Investor Category | Subscription (Times) |
|---|---|
| QIBs | 182.65x |
| NIIs | 42.36x |
| RIIs | 5.64x |
| Total | 63.86x |
What Does Anthem Biosciences Do?
Founded in 2006, Anthem Biosciences Ltd is a high-growth Contract Research, Development, and Manufacturing Organization (CRDMO). It serves over 550 clients across 44+ countries, with major markets in North America and Europe.
Key Business Highlights:
-
81.65% of FY25 revenue came from CRDMO operations.
-
Specializes in new chemical & biological entities.
-
Supplies enzymes, peptides, probiotics, and other specialty ingredients.
-
Engaged in cutting-edge R&D in RNAi, ADCs, and green chemistry.
-
Strategic US tie-up with Davos Pharma for market penetration.
Its integrated model covering drug discovery to commercial manufacturing gives it a significant edge over traditional CROs.
How to Check Anthem Biosciences IPO Allotment Status?
Here’s how investors can check their allotment status:
On BSE:
-
Visit: BSE IPO Status
-
Select Equity > Choose Anthem Biosciences Ltd
-
Enter PAN/Application No. > Click Search
On NSE:
-
Visit: NSE Allotment Page
-
Select Equity IPO > Pick Anthem Biosciences Ltd
-
Enter PAN & App Number > Click Submit
On KFinTech (Registrar):
-
Go to: KFin IPO Status
-
Choose IPO Name > Enter PAN/App No./DP ID
-
Solve Captcha > Click Submit
Note: If you’re allotted shares, they will reflect in your demat account by 18 July, and refunds for unallotted applications will be processed the same day.
Final Thoughts: Listing Day Outlook
With oversubscription at 63.86 times and a strong GMP, Anthem Biosciences IPO is on track for a power-packed listing this Monday. Long-term investors are attracted to its biotech innovation, strong global clientele, and growing demand for outsourced pharma services. The IPO’s structure being a pure OFS may limit immediate capital deployment by the company, but fundamentals remain promising.
Keep an eye on 21st July – the stock may open significantly above its issue price, rewarding early investors handsomely.
Know more about IPO Updates
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
